MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/2162402x.2023.2214478

Медицинская библиотека · Oncoimmunology · 2023

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.

Koh Benjamin, Tan Darren Jun Hao, Lim Wen Hui, Wong Jeffrey S L, Ng Cheng Han, Chan Kai En, Wang Meng, Yong Wei Peng, Dan Yock Young, Wang Louis Z, Tan Nigel, Muthiah Mark, Kow Alfred, Syn Nicholas L, Huang Daniel Q, Yau Thomas

ОбзорПоддержка исследования: вне правительства СШАСтатьяПеревод пока не подготовлен

Аннотация

The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25-30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and mechanistic biomarkers and novel treatment strategies are urgently needed for patients who present with or acquire resistance to first-line ICI-based therapies. The recent approval of the STRIDE regimen has also engendered new questions, such as patient selection factors (e.g. portal hypertension and history of variceal bleed) and biomarkers, and the optimal combination and sequencing of ICI-based regimens. Triumphs in the setting of advanced HCC have also galvanized considerable interest in the broader application of ICIs to early- and intermediate-stage diseases, including clinical combination of ICIs with locoregional therapies. Among these clinical contexts, the role of ICIs in liver transplantation - which is a potentially curative strategy unique to HCC management - as a bridge to liver transplant in potential candidates or in the setting of post-transplant recurrence, warrants investigation in view of the notable theoretical risk of allograft rejection. In this review, we summarize and chart the landscape of seminal immuno-oncology trials in HCC and envision future clinical developments.

Для цитирования: Koh Benjamin, Tan Darren Jun Hao, Lim Wen Hui, Wong Jeffrey S L, Ng Cheng Han, Chan Kai En, Wang Meng, Yong Wei Peng, Dan Yock Young, Wang Louis Z, Tan Nigel, Muthiah Mark, Kow Alfred, Syn Nicholas L, Huang Daniel Q, Yau Thomas. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.. Oncoimmunology. 2023. DOI: 10.1080/2162402x.2023.2214478.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.